Download MendeleyEnhancing the apo protein tyrosine phosphatase non-receptor type 2 crystal soaking strategy through inhibitor-accessible binding sites.
Bester, S.M., Linwood, R., Kataoka, R., Wu, W.I., Mou, T.C.(2024) Acta Crystallogr F Struct Biol Commun
- PubMed: 39177701
- DOI: https://doi.org/10.1107/S2053230X24007866
- Primary Citation of Related Structures:
9C54, 9C55, 9C56 - PubMed Abstract:
Protein tyrosine phosphatase non-receptor type 2 (PTPN2) has recently been recognized as a promising target for cancer immunotherapy. Despite extensive structural and functional studies of other protein tyrosine phosphatases, there is limited structural understanding of PTPN2. Currently, there are only five published PTPN2 structures and none are truly unbound due to the presence of a mutation, an inhibitor or a loop (related to crystal packing) in the active site. In this report, a novel crystal packing is revealed that resulted in a true apo PTPN2 crystal structure with an unbound active site, allowing the active site to be observed in a native apo state for the first time. Key residues related to accommodation in the active site became identifiable upon comparison with previously published PTPN2 structures. Structures of PTPN2 in complex with an established PTPN1 active-site inhibitor and an allosteric inhibitor were achieved through soaking experiments using these apo PTPN2 crystals. The increased structural understanding of apo PTPN2 and the ability to soak in inhibitors will aid the development of future PTPN2 inhibitors.
Organizational Affiliation:
Pfizer Boulder Research and Development, Boulder, CO 80301, USA.
